Davy Global Fund Management Ltd holds $8.86 million worth of shares in Johnson & Johnson (NYSE:JNJ)


Davy Global Fund Management Ltd decreased its holdings of Johnson & Johnson (NYSE:JNJ – Get Rating) shares by 0.4% during the 1st quarter, HoldingsChannel.com reports. The institutional investor held 50,007 shares of the company after selling 180 shares during the period. Johnson & Johnson owns around 1.4% of the holdings of Davy Global Fund Management Ltd, making it its 15th largest position. Davy Global Fund Management Ltd’s holdings in Johnson & Johnson were worth $8,863,000 when it last filed with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Family CFO Inc acquired a new position in Johnson & Johnson during the fourth quarter worth $26,000. Steward Financial Group LLC bought a new stake in Johnson & Johnson stock in Q4 worth $34,000. Joseph P. Lucia & Associates LLC bought a new equity stake in Johnson & Johnson in Q1 for $38,000. Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson stock by 41.4% in Q1. Advocacy Wealth Management Services LLC now owns 229 shares of the company worth $41,000 after acquiring 67 additional shares last quarter. Finally, Gibson Wealth Advisors LLC purchased a new equity stake in Johnson & Johnson in Q4 for $49,000. Institutional investors and hedge funds own 68.78% of the company’s shares.

Changes to analyst ratings

JNJ has been the subject of several recent analyst reports. Credit Suisse Group raised its price target on Johnson & Johnson shares from $200.00 to $205.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research note. Daiwa Capital Markets launched a hedge on Johnson & Johnson shares in a Wednesday, June 22 research note. They gave the company an “outperform” rating. UBS Group cut its price target on Johnson & Johnson shares from $185.00 to $180.00 in a research report on Thursday. Wells Fargo & Company raised its price target on Johnson & Johnson stock from $190.00 to $195.00 and gave the company an “overweight” rating in a Wednesday, July 13 research report. Finally, Goldman Sachs Group raised its price target on Johnson & Johnson shares from $163.00 to $181.00 and gave the company a “neutral” rating in a Tuesday, April 12 research report. Four analysts gave the stock a hold rating, six gave the stock a buy rating and one gave the stock a strong buy rating. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Price Performance

NYSE:JNJ shares opened at $172.12 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt ratio of 0.39. The company has a market capitalization of $452.92 billion, a PE ratio of 25.05, a P/E/G ratio of 3.48 and a beta of 0.63. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a 50-day moving average price of $176.25 and a two-hundred-day moving average price of $174.36.

Johnson & Johnson (NYSE:JNJ – Get Rating) last reported results on Tuesday, July 19. The company reported earnings per share of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. The company posted revenue of $24.02 billion in the quarter, versus analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company’s quarterly revenue increased 3.0% year over year. In the same quarter last year, the company earned earnings per share of $2.48. Stock analysts expect Johnson & Johnson to post EPS of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Monday, August 22. Johnson & Johnson’s payout ratio is 65.79%.

Insider Trading at Johnson & Johnson

Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares in a trade dated Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is available at this link. Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares in a trade dated Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is available at this link. Additionally, CAO Robert J. Decker sold 8,462 shares in a trade dated Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company, valued at $2,785,140. The disclosure of this sale can be found here. Insiders own 0.35% of the shares of the company.

Johnson & Johnson Company Profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.